U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000133: Small Cell Lung Cancer PRO
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000133: Small Cell Lung Cancer PRO

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Oncologic Diseases (OOD)
Division of Oncology 2 (DO2)

DDT COA Number
DDT COA #000133

Instrument Name
Small cell lung cancer (SCLC) symptom measure

Disease/Condition
Small cell lung cancer

Concept of Interest
SCLC symptom severity

Context of Use
Adult patients (> 18 years) with clinician-confirmed diagnosis of limited or extensive stage SCLC with Eastern Cooperative Oncology Group performance status of 0 to 2 regardless of the lines of therapy being administered

COA Type
PRO

Qualification Stage
Letter of Intent-Accepted

Requestor(s)
Critical Path Institute: Patient- Reported Outcome (PRO) Consortium, Small Cell Lung Cancer Working group

Contact(s)
Sonya Eremenco

Date Accepted into CDER’s COA Qualification Program
July 6, 2020

Submission and Regulatory Correspondence History

Qualification Submission Date FDA Submission Decision & Recommendations Date
Letter of Intent 4/28/20 FDA Response (Accepted) 7/6/20
Back to Top